As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Phio Pharmaceuticals Corp. The largest reported stake is CVI Investments, Inc.'s, at 9.9%. 9 filings are on record since August 7, 2025 (Schedule 13G/A, February 17, 2026).
Sell to companies like Phio Pharmaceuticals Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 1,194,719 · Sole dispositive: 0 · Shared dispositive: 1,194,719 · SCHEDULE 13G/A, 2026-02-17
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 1,142,556 · Sole dispositive: 0 · Shared dispositive: 1,142,556 · SCHEDULE 13G/A, 2026-02-13
- · Reporting person: Orca Capital AG · Sole voting: 538,707 · Shared voting: 0 · Sole dispositive: 538,707 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-12-11
- · Holder: Orca Capital AG · Percent: 6.5% · SCHEDULE 13G/A
- · Holder: Orca Capital AG · Percent: 4.9% · SCHEDULE 13G/A
Phio Pharmaceuticals Corp. has 9 Schedule 13D or 13G filings on record since 2025-08-07. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| CVI Investments, Inc. | 9.9% | 1,194,719 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| 9.1% | 1,142,556 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 | |
| Orca Capital AG | 4.9% | 538,707 | SCHEDULE 13G/A, 2025-12-11 | 2025-12-08 |
Holding shares or following this stake? See who's behind Phio Pharmaceuticals Corp. and the warning signs.
Free to see. No signup.
Keep reading
More on Phio Pharmaceuticals Corp. and the records around it.
Phio Pharmaceuticals Corp. elsewhere on the record
- Leadership changes Jul 2026
- Form D filing Nov 2025
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Phio Pharmaceuticals Corp.
Get an email when Phio Pharmaceuticals Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Phio Pharmaceuticals Corp.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Phio Pharmaceuticals Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Phio Pharmaceuticals Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| CVI Investments, Inc. | 0 | 1,194,719 | 0 | 1,194,719 | SCHEDULE 13G/A, 2026-02-17 |
| Heights Capital Management, Inc. | 0 | 1,194,719 | 0 | 1,194,719 | SCHEDULE 13G/A, 2026-02-17 |
| Mitchell P. Kopin | 0 | 1,142,556 | 0 | 1,142,556 | SCHEDULE 13G/A, 2026-02-13 |
| Daniel B. Asher | 0 | 1,142,556 | 0 | 1,142,556 | SCHEDULE 13G/A, 2026-02-13 |
| Intracoastal Capital LLC | 0 | 1,142,556 | 0 | 1,142,556 | SCHEDULE 13G/A, 2026-02-13 |
| Orca Capital AG | 538,707 | 0 | 538,707 | 0 | SCHEDULE 13G/A, 2025-12-11 |
The latest filing names Phio Pharmaceuticals Corp., with its principal executive office as 411 Swedeland Road, Suite 23-1080, King of Prussia, PA 19406 (SCHEDULE 13G/A, 2026-02-17).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Orca Capital AG | 4.9% | SCHEDULE 13G/A |
| 2025-11-06 | Orca Capital AG | 9.8% | SCHEDULE 13G/A |
| 2025-11-07 | Mitchell P. Kopin | 7% | SCHEDULE 13G/A |
| 2025-11-10 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2025-11-12 | Orca Capital AG | 4.9% | SCHEDULE 13G/A |
| 2025-11-24 | Orca Capital AG | 6.5% | SCHEDULE 13G/A |
| 2025-12-11 | Orca Capital AG | 4.9% | SCHEDULE 13G/A |
| 2026-02-13 | Mitchell P. Kopin | 9.1% | SCHEDULE 13G/A |
| 2026-02-17 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G/A |
Questions about who owns Phio Pharmaceuticals Corp.
Who owns Phio Pharmaceuticals Corp.?
On this page, 2 holders' latest ownership filings report 5% or more of Phio Pharmaceuticals Corp.: CVI Investments, Inc. (9.9%, Schedule 13G/A, filed 2026-02-17) and Mitchell P. Kopin (9.1%, Schedule 13G/A, filed 2026-02-13).
Who are the largest shareholders of Phio Pharmaceuticals Corp.?
By the share each holder's latest filing reports, the largest holders of Phio Pharmaceuticals Corp. on this page are CVI Investments, Inc. (9.9%) and Mitchell P. Kopin (9.1%).
When did CVI Investments, Inc. buy into Phio Pharmaceuticals Corp.?
The filings give report dates, not purchase dates. The earliest filing from CVI Investments, Inc. on this page is the Schedule 13G, filed 2025-11-10, reporting 9.9%; its latest, Schedule 13G/A filed 2026-02-17, reports 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Phio Pharmaceuticals Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 21, 2026 | Leadership change: R. Todd Plott appointed | — | Leadership changes | Source |
| November 12, 2025 | Form D, private offering | $1.42M sold | Form D page | Source |
| August 4, 2025 | Form D, private offering | $232K sold | Form D page | Source |
| January 28, 2025 | Form D, private offering | $208K sold | Form D page | Source |
| January 28, 2025 | Form D, private offering | $153K sold | Form D page | Source |
| January 28, 2025 | Form D, private offering | $266K sold | Form D page | Source |
| January 7, 2025 | Form D, private offering | $30K sold | Form D page | Source |
| January 3, 2025 | Form D, private offering | $55K sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Phio Pharmaceuticals Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.